Daniel Norman, MD
Sleep Medicine · Los Angeles, CANPI 1730198730
Payments from drug & device makers
Across 805 payments — averaging $5224.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$3.5M
- Harmony Biosciences LLC$225K
- Jazz Pharmaceuticals Inc.$214K
- Alkermes, Inc.$155K
- Avadel CNS Pharmaceuticals, LLC$52K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- plus $14K from 19 others
Across 7 payments — averaging $1231.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Harmony Biosciences LLC$9K
- GSK$73
What the payments were for
- Consulting fees$9,15439%
- Speaking & faculty fees$5,40023%
- Travel & lodging$8674%
- Food & beverage$7,91733%
- Education$3501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 158 | $3,526,871 |
| Harmony Biosciences LLC | 124 | $224,879 |
| Jazz Pharmaceuticals Inc. | 185 | $214,227 |
| Alkermes, Inc. | 196 | $154,634 |
| Avadel CNS Pharmaceuticals, LLC | 23 | $51,688 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $19,088 |
| Cipla USA Inc. | 11 | $7,341 |
| Pear Therapeutics (US), Inc. | 1 | $3,079 |
| Inspire Medical Systems, Inc. | 12 | $1,555 |
| Eisai Inc. | 9 | $746 |
| Axsome Therapeutics, Inc. | 15 | $334 |
| Akorn Operating Company LLC | 12 | $193 |
| Arbor Pharmaceuticals, Inc. | 9 | $181 |
| Idorsia Pharmaceuticals US Inc | 9 | $171 |
| Lilly USA, LLC | 6 | $133 |
| Merck | 7 | $118 |
| Noctrix Health, Inc. | 1 | $108 |
| Resmed Corp | 1 | $92 |
| Itamar Medical Inc | 1 | $85 |
| Azurity Pharmaceuticals, Inc. | 5 | $81 |
| AstraZeneca | 2 | $41 |
| Optinose US, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $40 |
| Grifols USA, LLC | 1 | $25 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,205,767 in reported general payments places this provider in the 95th percentile of 200 sleep medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XyremSodium Oxybate | 14 | $301,218 |
| LumryzSodium Oxybate | 12 | $139,447 |
| DayvigoLemborexant | 54 | $21,357 |
| BelsomraSuvorexant | 37 | $16,720 |
| QuviviqDaridorexant Hcl | 24 | $11,230 |
| Mirtazapine | 63 | $2,236 |
| Zolpidem Tartrate | 38 | $1,503 |
| Azelastine Hcl | 40 | $1,409 |
| Modafinil | 33 | $1,231 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $1,005 |
| Ramelteon | 18 | $879 |
| Acetazolamide | 21 | $689 |
| Armodafinil | 18 | $382 |
| Fluticasone Propionate | 23 | $377 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLCLumryz | $51,688 | $139,44712 claims |
| Eisai Inc.Dayvigo | $746 | $21,35754 claims |
| MerckBelsomra | $118 | $16,72037 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $171 | $11,23024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 200 sleep medicine providers in California.
Other sleep medicine in Los Angeles
- Arun RamachandranLos Angeles$17K
- Payam ShadiLos Angeles$10K
- Emmanuel MignotStanford$4.7M
- Atul MalhotraSan Diego$1.4M
- Lisa ShivesSan Diego$1.4M
- Haramandeep SinghSan Ramon$1.3M
- Logan SchneiderStanford$506K
- Tony MasriLos Gatos$327K
- Clete KushidaStanford$231K
- Sam KashaniSanta Monica$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.